<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03872050</url>
  </required_header>
  <id_info>
    <org_study_id>RosMigInterview</org_study_id>
    <nct_id>NCT03872050</nct_id>
  </id_info>
  <brief_title>Deep Phenotyping of Rosacea and Migraine</brief_title>
  <official_title>Deep Phenotyping of Rosacea and Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to deep phenotype patients with rosacea and migraine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rosacea and migraine are common disorders that overlap in epidemiology, symptoms, trigger
      factors, and distribution in the trigeminal area. Recent studies establish a connection
      between the two disorders, which needs to be investigated.

      The purpose of this study is investigate the link between the two disorders by deep
      phenotyping through semi-structured interviews.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 14, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of migraine in rosacea cohort</measure>
    <time_frame>60 minutes</time_frame>
    <description>Prevalence of patients in rosacea cohort who fulfill diagnostic criteria for migraine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of rosacea in migraine cohort Prevalence of rosacea in migraine cohort</measure>
    <time_frame>60 minutes</time_frame>
    <description>Prevalence of patients in migraine cohort who fulfill diagnostic criteria for rosacea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of migraine subtypes in rosacea cohort</measure>
    <time_frame>60 minutes</time_frame>
    <description>Prevalence of patients in rosacea cohort who fulfill diagnostic criteria for subtypes of migraine according to international headache society classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of rosacea subtypes in migraine cohort</measure>
    <time_frame>60 minutes</time_frame>
    <description>Prevalence of patients in migraine cohort who fulfill diagnostic criteria for subtypes of rosacea</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Migraine</condition>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Rosacea</arm_group_label>
    <description>Patients who have been diagnosed with rosacea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Migraine</arm_group_label>
    <description>Patients who have been diagnosed with migraine</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>No intervention apart from tests, including interview</intervention_name>
    <description>No interventions</description>
    <arm_group_label>Migraine</arm_group_label>
    <arm_group_label>Rosacea</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Mouthswab for DNA-sampling
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Rosacea

          -  patients invited to participate through 3 different clinics in Copenhagen and Zealand,
             Denmark

        Migraine

          -  patients attending the outpatient clinic of the Danish Headache Center invited to
             participate
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis with either rosacea and/or migraine

        Exclusion Criteria:

          -  does not want to participate

          -  cannot co-operate to investigation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Messoud Ashina, MD, PhD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Glostrup</city>
        <state>Zealand</state>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Nita Katarina Frifelt Wienholtz</investigator_full_name>
    <investigator_title>Principal Investigator, Medical Doctor, PhD Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

